Efficacy of Inotuzumab ozogamicin when used as salvage / bridging therapy prior to CD19-directed CAR-T therapy in relapsed / refractory B-ALL: A single-center experience

Anupa John, Hasmukh Jain, Manju Sengar

Introduction:

High disease burden before CAR-T compromises outcomes in relapsed/refractory B-ALL. • InO provides effective cytoreduction and may serve as an effective debulking strategy prior to CAR-T cell therapy. • We evaluated the outcomes and toxicities of InO when used as salvage / bridging prior to talicabtagene autoleucel (Tali-cel).

Conclusion:

InO provided effective cytoreduction and successful bridging to CAR-T in R/R B-ALL. CART infusion was feasible in 95.7%, with manageable toxicity.